Search
Vaccines including conserved antigens from Streptococcus pneumoniae & nontypeable Haemophilus influenzae have the potential to reduce of otitis media.
Otitis media (OM) is a common childhood disease characterised by middle ear inflammation following infection
In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Streptococcus pneumoniae, Moraxella catarrhalis, and nontypeable Haemophilus influenzae is associated with otitis media
Haemophilus haemolyticus is often incorrectly categorized as nontypeable Haemophilus influenzae (NTHI) upon culture. PCR analyses of 266 NTHI-like nasopharyngea
Demonstrate mucosal bacterial infection in children with otitis media with effusion (OME).
The Kids's Dr Ruth Thornton is one of 12 finalists in the annual national Fresh Science competition with her research into middle-ear infections.
The Kids is investigating whether a cystic fibrosis medication may be the answer to ear infections, reducing the need for antibiotics and surgery.
Congratulations to Telethon Kids Institute researcher Dr Chris Brennan-Jones who was named Woodside Early Career Scientist of the Year at last night’s 2020 Premier’s Science Awards.
In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.